Latest Breaking News On - Trishula therapeutics inc - Page 1 : comparemela.com

Carisma Therapeutics Announces Changes to its Board of Directors

Carisma Therapeutics Announces Changes to its Board of Directors
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesGettysburg collegeJohn hohnekerShveta digheBurroughs wellcomeSanford zweifachChidozie ugwumbaTrishula therapeutics incGlobal head of developmentRutgers school of biomedicalBiotheryx incDimension therapeutics incBoard of directors curis incSonata therapeutics incTorque therapeutics inc

Carisma Therapeutics (CARM) Announces Board Changes

Carisma Therapeutics (CARM) Announces Board Changes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesBurroughs wellcomeSanford zweifachJohn hohnekerChidozie ugwumbaUniversity of medicineEvelo biosciences incRutgers medical schoolAravive incAudit committee of the boardUniversity of north carolina at chapel hillTrishula therapeutics incGlobal head of developmentBiotheryx incDimension therapeutics inc

Curis Appoints John A Hohneker, M D To Board Of Directors

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

Evelo biosciencesBurroughs wellcomeJohna hohnekerJames dentzerGettysburg collegeCuris incTherapeutics incUniversity of north carolina at chapel hillHumanigen incBiotheryx incHealth sciencesGlobal head of developmentRutgers school of biomedicalDrug administrationAravive incTrishula therapeutics inc

BioSpace Movers & Shakers, May 21

Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.

United statesStephen bassoInozyme pharmaPhelps mcnamaraR michael carruthersSynageva biopharmaPeter pechanSierk poettingJens hoslteinLucio tozziBradley gloverBristol myers squibbMark pennesiGuy levyEvelo biosciencesTyler ralston

Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer Trishula TherapeuticsJanuary 21, 2021 GMT Trishula Continues to Advance Development of TTX-030 in collaboration with AbbVie SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 (GLOBE NEWSWIRE) Today Trishula Therapeutics, Inc., a clinical stage, privately held company developing TTX-030, a first-in-class anti-CD39 antibody in advanced cancers, announced the appointment of Anil Singhal, Ph.D., MBA, as Chief Executive Officer, effective immediately. Dr. Singhal will also serve on the Trishula Board of Directors. “The Board of Directors of Trishula Therapeutics is thrilled to bring Anil to the company with his stellar track record in advancing novel oncology therapies from early clinical development through to approval,” said Luke Evnin, Ph.D., Chairman of Trishula’s Board of Directors. “We have complete confidenc

Luke evninAdicet bioJanet graesserTrishula therapeutics incAdjunct associate professor at university of washingtonTrishula continues to advance developmentOncoresponse incEarly oncology development at abbvieAdvance developmentTrishula therapeuticsAnil singhalChief executive officerTrishula boardCanaan partnersVice presidentEarly oncology development